ArticleThe Journal of infectious diseases2025
Respiratory Syncytial Virus and Human Metapneumovirus Respiratory Hospitalizations and Outcomes in Colorado Adults ≥50 Years of Age: 2016-2023.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Development and Validation of a Nomogram for Predicting Severe Respiratory Illness in Children with Isolated Human Metapneumovirus Infection.Children (Basel, Switzerland) · 2026Article
- Hospitalisation Burden of Human Metapneumovirus and Respiratory Syncytial Virus in Adults by Age and Comorbidity Status in Scotland: A Retrospective Analysis.Infectious diseases and therapy · 2026Article
- Characteristics and Risk Factors Associated With Hospitalization and Severe Disease in Patients Aged ≥ 60 Years With Human Metapneumovirus Infection Over Three Consecutive Seasons (2021-2024) in Valladolid, Spain. The VALLAVIRUS Study.Influenza and other respiratory viruses · 2026Article
- Human Metapneumovirus-associated Hospital Burden in Older Adults in Scotland: A Retrospective Analysis.Open forum infectious diseases · 2026Article
- Immunosenescence and susceptibility to respiratory viruses: a state-of-the-art review.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Severe acute respiratory distress syndrome associated with human metapneumovirus infection in a morbidly obese adult.IDCases · 2026Article
- Structural basis for childhood antibody recognition of the human metapneumovirus fusion protein.Nature communications · 2025Article
- Structural Basis for Childhood Antibody Recognition of The Human Metapneumovirus Fusion Protein.bioRxiv : the preprint server for biology · 2025Article
- Review: Knowledge Gained and Gaps in Understanding in the 25 Years Since Human Metapneumovirus Was First Identified as a Cause of Human Disease.The Journal of infectious diseases · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmong older adults, respiratory syncytial virus (RSV) infection is a known cause of hospitalization, intensive care unit (ICU) admission, and mortality risk. The severity of the disease burden of human metapneumovirus (HMPV) among older adults is less well recognized. The objective of this study was to better understand risk factors for hospitalization with and outcomes in adults ≥50 years of age infected with HMPV and to compare these with RSV risk factors and outcomes.
methodsThis was a retrospective cohort analysis of adults 50-88 years of age in 93 medical facilities in the Colorado Hospital Association database between 2016 and 2023. RSV and HMPV, other respiratory infections, and comorbidities were identified using International Classification of Diseases, Tenth Revision codes and grouped by increasing numbers of comorbidities. Multivariate logistic regression was performed to estimate the risk of the various predictors on ICU admission, and mortality for both HMPV and RSV infection, adjusted for sex, age, and comorbidity.
resultsThe highest risk for ICU admission was chronic obstructive pulmonary disease (COPD) (RSV: adjusted odds ratio [aOR], 2.24 [95% confidence interval {CI}, 1.81-2.77], P < .001; HMPV: aOR, 2.99 [95% CI, 2.13-4.19], P < .001), and those with neuromuscular disease without dementia (RSV: aOR, 2.33 [95% CI, 1.98-2.75], P < .001; HMPV: aOR, 2.22 [95% CI, 1.75-2.80], P < .001). Age significantly increased the odds of mortality among RSV-infected but not HMPV-infected patients. Neurological disorders with dementia were the highest comorbid risk factor for RSV mortality (aOR, 4.16 [95% CI, 3.01-5.77]; P < .001), in contrast to COPD for HMPV mortality (aOR, 12.44 [95% CI, 3.02-51.17]; P < .001).
conclusionsHMPV infection poses a unique disease burden with specific high-risk comorbidities among the older adult population distinct from that of RSV and warrants further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.